Funding for this research was provided by:
Swiss Cancer Research Foundation (KLS-4304-08-2017)
Received: 9 October 2019
Accepted: 28 November 2019
First Online: 30 December 2019
Ethics approval and consent to participate
: The study has been designed according to the Declaration of Helsinki [CitationRef removed], the Human Research Act (HRA) [CitationRef removed], and the Human Research Ordinance (HRO) [CitationRef removed]. The study protocol Version 3.0, dated January 26th 2019, was approved by the Ethikkommission Zentral- und Nordwestschweiz (EKNZ; vote: EKNZ 2018–01115, dated August 28th 2018 and amendment dated Mars 14th 2019). In addition, ethical approval was obtained from the Kantonale Ethikkommission Zürich. Consistent with good clinical practice, patients are informed about participation in the study, its implications and written consent is obtained. The participation is voluntary and can be withdrawn at any time during the study.
: Not applicable.
: The authors declare that they have no competing interests.